This clinical trial is focused on studying a condition called Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). CIDP is a neurological disorder that causes progressive weakness and impaired sensory function in the legs and arms. The study is testing a treatment called nipocalimab, which is given as a solution for infusion. The purpose of the study is to evaluate how effective and safe nipocalimab is in delaying the return of symptoms in adults with CIDP who initially respond to the treatment.

Participants in the study will receive either nipocalimab or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not biased. The study will take place over several stages, and participants will be monitored for any changes in their condition, as well as any side effects they may experience.

The trial will involve regular assessments to track the progression of CIDP symptoms and the overall health of the participants. These assessments will include checking muscle strength, grip strength, and other physical abilities. The study aims to provide valuable information on whether nipocalimab can be a beneficial treatment option for people living with CIDP.